索尼德吉联合芦可替尼治疗骨髓纤维化的安全性与疗效:一项1b/2期剂量探索研究
这项开放标签研究在未接受过JAK抑制剂治疗的骨髓纤维化患者中评估索尼德吉联合芦可替尼。1b期确定最大耐受剂量/推荐2期剂量为索尼德吉400 mg每日联合芦可替尼20 mg每日两次;2期第24周和48周脾脏体积缩小≥35%的患者分别为44.4%和29.6%。联合方案耐受性良好,但总体获益有限,将不再进一步开发。
要点
- 最大耐受剂量/推荐2期剂量为索尼德吉400 mg每日联合芦可替尼20 mg每日两次。
- 第24周和48周脾脏体积缩小≥35%者分别为44.4%和29.6%。
- 常见3/4级治疗相关不良事件为血肌酸磷酸激酶升高18%、贫血14%、血小板减少12%。
核心结论
- 联合方案耐受性良好,但与历史芦可替尼单药治疗相比总体获益有限,将不再在骨髓纤维化患者中进一步开发。
研究设计与样本
- 开放标签研究,纳入未接受过JAK抑制剂治疗的骨髓纤维化患者,共50例。
- 1b期主要目标为确定最大耐受剂量和/或推荐2期剂量,2期评估第24周和第48周脾脏体积缩小。
- 剂量递增阶段23例,1b期扩展和2期第一阶段27例。
主要发现
- 剂量递增阶段索尼德吉每日一次/芦可替尼每日两次的剂量为400/10 mg(1级,8例)、400/15 mg(2级,10例)、400/20 mg(3级,5例)。
- 2级有2例出现剂量限制性毒性:血肌酸磷酸激酶升高(3级和4级各1例)。
- 1b期扩展和2期第一阶段27例中,第24周和第48周脾脏体积缩小≥35%的患者分别为44.4%和29.6%。
- 第24周和第48周骨髓纤维化症状评估表总症状评分缩小≥50%的患者分别为42.0%和26.0%。
- 常见3/4级治疗相关不良事件为血肌酸磷酸激酶升高(18%)、贫血(14%)、血小板减少(12%)。
关键数值与推荐
- 最大耐受剂量/推荐2期剂量为索尼德吉400 mg每日联合芦可替尼20 mg每日两次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 与历史芦可替尼单药治疗相比总体获益有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The sonidegib and ruxolitinib combination was assessed in an open-label study in JAK inhibitor-naive patients with myelofibrosis (MF). The primary objective of phase 1b was to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and phase 2 was to assess spleen volume reduction at weeks 24 and 48. Fifty patients were enrolled. In the dose-escalation phase (n = 23), doses for sonidegib once daily/ruxolitinib twice daily were 400/10 mg (level 1, n = 8), 400/15 mg (level 2, n = 10), and 400/20 mg (level 3, n = 5). Two patients had dose-limiting toxicity at level 2: increased blood creatine phosphokinase (grades 3 and 4, n = 1 each). MTD/RP2D was determined as sonidegib 400 mg daily + ruxolitinib 20 mg twice daily. In phase 1b expansion and phase 2 stage 1 (n = 27), by weeks 24 and 48, ≥35% reduction in spleen volume was observed in 44.4% and 29.6% patients, respectively. By weeks 24 and 48, 42.0% and 26.0% patients had ≥50% reduction in Myelofibrosis Symptom Assessment Form total symptom score, respectively. Most common treatment-related adverse events (grade 3/4) were increased blood creatine phosphokinase (18%), anemia (14%), and thrombocytopenia (12%). Four deaths were reported due to multiple organ dysfunction syndrome (on-treatment; no relationship with study treatment), acute myeloid leukemia, MF progression, and aspiration pneumonia. Although well tolerated, this combination will not be further developed in MF patients due to modest overall benefit compared with historical ruxolitinib monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT01787552.
引用
- Gupta V, Wolleschak D, Hasselbalch H, et al. Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Adv. 2020. PMID: 32634234. doi:10.1182/bloodadvances.2019001212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。